Genes & Cancer

ERBB signaling in CTCs of ovarian cancer and glioblastoma

Anjali Geethadevi1, Deepak Parashar1, Erin Bishop1, Sunila Pradeep1 and Pradeep Chaluvally-Raghavan1,2

1 Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

2 Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA


Pradeep Chaluvally-Raghavan, email:

Keywords: circulating tumor cells; ERBB receptors; ovarian cancer; glioblastoma

Received: November 29, 2019 Accepted: December 22, 2017 Published: December 27, 2017


Circulating Tumor Cells (CTCs) are floating cell populations, which are resistant to anoikis after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate throughout the body. CTCs are considered as seed cells for metastasis, and thus isolation of CTCs does not require any invasive procedure. Based on the nature and location of ovarian cancer and glioblastoma, the role of CTCs and hematogenous (carried by blood) spreading of tumor cells in these cancers were not understood well. Dysregulation of epidermal growth factor receptor (EGFR/ERBB) family members due to their overexpression and/or mutation have been known to contribute to the etiology and progression of ovarian cancer and glioblastoma. However, the role of ERBB receptors on CTC formation of ovarian cancer and glioblastoma is not well established. This report highlights the role of ERBB family receptors on resistance to anoikis and CTC formation in ovarian cancer and glioblastoma. Recent research on CTCs demonstrates that capturing ERBB receptor positive cells from circulating system is an efficient approach to isolate CTCs for genomic and proteomic characterization of tumor cells. Therefore, ERBB-targeted isolation of CTCs would help to design therapy to treat cancer, determine drug responses and drug-resistant mechanisms in cancer patients.

PII: 162